Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

Arvinas Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Arvinas wird ein jährliches Gewinn- und Umsatzwachstum von 27.1% bzw. 35.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 31.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -49% betragen.

Wichtige Informationen

26.8%

Wachstumsrate der Gewinne

31.3%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.6%
Wachstumsrate der Einnahmen	35.1%
Zukünftige Eigenkapitalrendite	-104.5%
Analystenabdeckung	Good
Zuletzt aktualisiert	17 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Arvinas: Behind The Huge Rally

Mar 03

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Feb 25

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

Aug 13

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Aug 19

Arvinas: Still Holding, Just Not Buying More

May 23

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Feb 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ARVN - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	291	-284	-254	-219	15
12/31/2025	219	-307	-291	-255	18
12/31/2024	182	-256	-195	-202	17
3/31/2024	71	-355	-356	-354	N/A
12/31/2023	79	-367	-351	-348	N/A
9/30/2023	159	-295	-340	-336	N/A
6/30/2023	158	-298	-323	-318	N/A
3/31/2023	137	-301	-313	-308	N/A
12/31/2022	131	-282	-280	-273	N/A
9/30/2022	127	-253	-246	-238	N/A
6/30/2022	103	-233	503	510	N/A
3/31/2022	75	-213	536	541	N/A
12/31/2021	54	-191	555	559	N/A
9/30/2021	23	-180	562	566	N/A
6/30/2021	21	-164	-142	-138	N/A
3/31/2021	21	-139	-118	-112	N/A
12/31/2020	26	-119	-96	-90	N/A
9/30/2020	24	-99	-83	-77	N/A
6/30/2020	47	-86	-59	-53	N/A
3/31/2020	45	-78	-52	-45	N/A
12/31/2019	43	-70	-47	-41	N/A
9/30/2019	42	-65	-42	-37	N/A
6/30/2019	15	-173	-54	-50	N/A
3/31/2019	14	-179	-51	-48	N/A
12/31/2018	14	-240	-19	-16	N/A
9/30/2018	13	-233	22	24	N/A
6/30/2018	12	-114	26	28	N/A
3/31/2018	10	-98	30	31	N/A
12/31/2017	8	-29	N/A	5	N/A
12/31/2016	7	-12	N/A	-19	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ARVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: ARVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: ARVN wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: ARVNDie Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.1% pro Jahr).

Hohe Wachstumseinnahmen: ARVNDie Einnahmen des Unternehmens (35.6% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ARVN wird voraussichtlich in 3 Jahren unrentabel sein.

Arvinas Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 17%

Consensus EPS estimates upgraded to US$5.13 loss

Consensus EPS estimates upgraded to US$5.76 loss

Price target decreased by 7.5% to US$55.82

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

Recent updates

Arvinas, Inc. Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE)

Consensus revenue estimates increase by 17%

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Arvinas, Inc. Appoints Randy Teel as Chief Business Officer

Arvinas, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates upgraded to US$5.13 loss

Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee

Arvinas: Behind The Huge Rally

Full year 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates upgraded to US$5.76 loss

Arvinas, Inc. announced that it has received $349.999871 million in funding from a group of investors

What Arvinas, Inc.'s (NASDAQ:ARVN) 28% Share Price Gain Is Not Telling You

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. Announces Chief Financial Officer Changes

Arvinas, Inc. and Pfizer Inc. Announces That the U.S. Food and Drug Administration Has Granted Fast Track Designation for the Investigation of Vepdegestrant (Arv-471) for Monotherapy

Arvinas, Inc. Announces Appointment of Jared Freedberg as General Counsel

Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program

Price target decreased by 7.5% to US$55.82

New minor risk - Share price stability

Consensus estimates of losses per share improve by 13%

Price target decreased by 7.6% to US$55.80

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 10.0% to US$60.38

Arvinas, Inc. Announces the Presentation of Interim Data from the its Phase 1/2 Clinical Trial for Bavdegalutamide

Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

Consensus revenue estimates increase by 17%

News Flash: Analysts Just Made A Notable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) Forecasts

New major risk - Revenue and earnings growth

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

Arvinas and Pfizer Wins Innovation Passport Designation by the U.K. Innovative Licensing and Access Pathway Steering Group for Vepdegestrant

New minor risk - Share price stability

Arvinas, Inc. Announces Changes to its Board of Directors

Arvinas, Inc. Announces Interim Data from Phase 1/2 Dose Escalation and Expansion Trial of ARV-766

Consensus revenue estimates increase by 10%, EPS downgraded

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

There's Reason For Concern Over Arvinas, Inc.'s (NASDAQ:ARVN) Price

Consensus EPS estimates fall by 12%

Calculating The Fair Value Of Arvinas, Inc. (NASDAQ:ARVN)

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas Announces Changes to Its Board of Directors

Arvinas, Inc. Announces in Post-Hoc Analysis from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Expects VERITAC-2 Phase 3 Trial Population Achieve Clinical Benefit Rate of 62.5%

Price target decreased to US$83.90

Arvinas, Inc. Announces Initial Results from Phase 2 Cohort Expansion Portion (VERITAC) of Phase 1/2 Study with ARV-471 Co-Developed with Pfizer Inc

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Arvinas, Inc. Appoints Paul McInulty as Senior Vice President, Regulatory Affairs

Arvinas initiated Overweight at Barclays on attractive therapeutic platform

Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment

Arvinas, Inc. Announces Changes to its Board of Directors

Chief Medical Officer exercised options and sold US$69k worth of stock

Arvinas, Inc. Appoints Lisa Sinclair as Senior Vice President, Corporate Operations

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Arvinas, Inc. Appoints John Northcott as Chief Commercial Officer

Arvinas: Still Holding, Just Not Buying More

Consensus EPS estimates fall by 12%

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new directors

CFO & Treasurer exercised options and sold US$810k worth of stock

Chief Scientific Officer exercised options to buy US$226k worth of stock.

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Chief Scientific Officer notifies of intention to sell stock

Arvinas, Inc. Announces Completed Phase 1 and Interim Phase 2 ARDENT Data for Bavdegalutamide (ARV-110), A Novel PROTAC® Degrader Targeting the Androgen Receptor

Arvinas, Inc. Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 Ardent Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to Present At 2022 ASCO GU Meeting

Arvinas: One Of The Most Interesting Science-Heavy Emerging Biopharma

Independent Director exercised options and sold US$793k worth of stock